Drug intelligence / Profile preview

BRI-301

Development stage: Preclinical
Lead developer: BRI Pharma
Modality: Small Molecules

Overview

BRI-301 is a small-molecule therapeutic candidate being developed by BRI Pharma, a Japanese biotechnology company focused on neurodegenerative diseases. It acts through a novel multi-target mechanism as an activator of T-type calcium channels, calmodulin-dependent protein kinase (CaMK), and the proteasome. This triple-action approach is designed to provide disease-modifying effects by enhancing synaptic function and promoting the clearance of pathogenic protein aggregates. BRI-301 is currently the lead candidate in BRI Pharma's pipeline and is being investigated for the treatment of Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), Parkinson's disease (PD), dystonia, and depression.

Targets

CaV3 (Caveolin-3)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)26S proteasome

Beyond the preview

Go deeper on BRI-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRI-301.

Explore the full profile